Moximed, Inc. Names Christopher Gleason as Chief Executive Officer

June 25, 2024 |

4 min read

Moximed today announced that Christopher Gleason has been appointed President and Chief Executive Officer (CEO).

● Gleason has a track record of leading teams and scaling innovative technology

FREMONT, Calif.--(BUSINESS WIRE)-- Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that Christopher Gleason has been appointed President and Chief Executive Officer (CEO).

Gleason is an experienced medical device leader who has successfully commercialized multiple disruptive medical technologies through periods of exponential growth and dramatically improved the delivery of patient care. Most recently, he was Vice President of Sales at Relievant (acquired by Boston Scientific Corporation for an upfront cash payment of $850MM and additional undisclosed milestone related payments). He previously served as Vice President of Sales of Interventional Urology at Teleflex and in other sales leadership roles at NeoTract prior to acquisition by Teleflex in 2017. Gleason also served in leadership roles at Xenex Healthcare and Acclarent at Johnson and Johnson.

“It is an honor to join Moximed as we expand access of the MISHA^® Knee System to the many knee OA patients in the U.S. who may benefit,” said Gleason. “I have spoken to a number of patients, and I’m inspired by the amazing stories of how the MISHA Knee System has positively impacted their lives. We have a talented team who is relentlessly dedicated to advancing patient care, and I look forward to helping Moximed realize its tremendous potential.”

“I’m thrilled to have Chris take the leadership role at Moximed and drive the expansion phase of the company,” said Moximed Co-Founder and CTO Anton Clifford, Ph.D. “We’re seeing tremendous clinical results from commercial use of the MISHA Knee System, and it’s the perfect time for Chris to broaden our commercial reach and enable greater product access for the benefit of patients.”

“The Board enthusiastically welcomes Chris Gleason as our new CEO,” said Josh Makower, M.D., Co-Founder and Chairman of the Board of Directors at Moximed. “Moximed has a transformational, breakthrough product for the treatment of medial compartment knee osteoarthritis, and it is exciting to see Chris step in to lead this talented and resilient team towards the establishment of the MISHA Knee System as a new standard of care for patients suffering from this widespread condition.”

“I have had the pleasure of being part of Chris’s success disrupting markets and creating businesses that generate over $100 million in annual revenues in two consecutive med-tech companies, NeoTract and Relievant. Now I look forward to him doing it again at Moximed.” noted Dave Amerson, Board Director, Moximed. “He is a uniquely qualified leader with expertise in commercial execution and fostering high performing cultures. I know he will relish the challenge of creating a new market in the orthopaedic space.”

About The MISHA^® Knee System

Moximed’s MISHA Knee System is for people with medial knee OA who failed to find relief from previous treatments. These patients continue to experience pain that interferes with daily activities, and are ineligible for, or unwilling to undergo, joint replacement due to age or absence of advanced OA.

Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease. OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life.

Reducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA Knee System is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery. The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step.ⁱ

The MISHA Knee System is FDA cleared.

About Moximed

Moximed’s technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss. Moximed is based in Fremont, California.

To learn more, visit www.moximed.com.

ⁱ Morgan OJ, Hillstrom HJ, Ranawat A, Fragomen AT, Rozbruch SR, Hillstrom R. Effects of a Medial Knee Unloading Implant on Tibiofemoral Joint Mechanics During Walking. J Orthop Res. 2019;37(10):2149-2156. doi:10.1002/jor.24379.